The radioprotective effect of solcoseryl

Bauer, Delphine; Locker, A.

doi:10.1007/bf01921520

Cited by 4 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prophylactic treatment with Actovegin on 6 consecutive days before the radiation did not reveal any preventive effect of Actovegin. In a similar study, Basu et al [33] examined the radioprotective effects of Actovegin in adult rats; while control animals died within 30 days, the rats treated with Actovegin 1 hour before irradiation had a statistically significant higher survival rate, as already described in the study of Bauer and Locker [31], thereby confirming their results. By contrast, Tamou and Trott [34] describe findings on the occurrence of radiation-induced ulcers in the rectum of rats where the results in the Actovegin group did not differ from control conditions.…”

Section: Wound Healing and Effects On Radiation-induced Damagesupporting

confidence: 57%

“…Many observations point to a possible protective effect of Actovegin against the effects of ionizing radiation. Bauer and Locker [31] investigated the effects of Actovegin on the survival of mice that have been irradiated by a lethal dose of gamma radiation. Application of Actovegin led concentration-dependently to a better survival of the Actovegin Ò -treated animals after 30 days following irradiation.…”

Section: Wound Healing and Effects On Radiation-induced Damagementioning

confidence: 99%

See 1 more Smart Citation

Actovegin®: a biological drug for more than 5 decades

Buchmayer

Pleiner

Elmlinger³

et al. 2011

Wien Med Wochenschr

View full text Add to dashboard Cite

Actovegin(®) is a biological drug manufactured from a natural source: it is a calf blood hemodialysate. Its therapeutic benefits stem from a variety of pharmacodynamic actions that can be summarized to a common goal, i.e. the enhancement of cellular metabolism; this results from an insulin-like activity mediated by Inositol-phospho-oligosaccharides. Actovegin(®) results in beneficial effects in several pathophysiological clinical settings including malfunction of the blood circulation and trophic disturbances in the brain, impairment of peripheral blood circulation and associated diseases, dermal transplants and acute and chronic wounds. Here, we give an overview of the pharmacodynamic actions of calf-blood hemidialysate and its beneficial effects in a variety of clinical settings.

show abstract

Section: Wound Healing and Effects On Radiation-induced Damagesupporting

confidence: 57%

Section: Wound Healing and Effects On Radiation-induced Damagementioning

confidence: 99%

Actovegin®: a biological drug for more than 5 decades

Buchmayer

Pleiner

Elmlinger³

et al. 2011

Wien Med Wochenschr

View full text Add to dashboard Cite

show abstract

“…Thereafter, the medium was switched to a differentiation medium (DM) containing DMEM, 1 % penicillin/streptomycin, 4 mM glutamine, 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate and 4 % horse serum (all from Life-Technologies, Carlsbad, CA, USA). Actovegin ® (Takeda Pharmaceutical, Ōsaka, Prefecture Osaka, Japan) (LOT Number 10946788) was added in five different concentrations (1,5,25,125, and 250 µg) to the DM. The control group was only treated with the normal DM.…”

Section: C2c12 Cell Culture and Treatmentmentioning

confidence: 99%

Comprehensive Analytics of Actovegin® and Its Effect on Muscle Cells

et al. 2017

View full text Add to dashboard Cite

The ingredients of Actovegin ® were analyzed and its effects on the muscle cell proliferation were investigated. C2C12 myoblasts were cultured in medium. Actovegin ® was added in five different concentrations (1, 5, 25, 125, and 250 µg) to the differentiation medium. The formations of proliferation factor Ki67 and myosin heavy chains were measured by immunofluorescence. The first primary antibody was anti-Ki67 and antiMf20. Cells were washed and treated with the second fluorochrome. Thirty-one Actovegin ® ingredients were found to contain significantly higher concentrations and twenty-nine ingredients were found to contain significantly lower concentrations, compared to the mean ranges as described in the literature for the normal physiological concentrations in human adult serum/plasma. A significant increase in the formation of Ki67 was observed in Actovegin ® groups, compared to controls. The mean area of myotubes was significantly increased in Actovegin ® groups. A significant decrease in the number of myotubes was observed. An increased myotube size (fusion) was observed. The intensity of Mf20 was significantly increased in Actovegin ® groups. It could be demonstrated that Actovegin ® contains many physiological substances in significantly higher and some in lower concentrations compared to human adult serum. Furthermore, it could be shown that Actovegin ® improves muscle cell proliferation.

show abstract

“…(e.g., angiopathy and ulcus cruris) (Buchmayer et al 2011;Chanh et al 1980;Lanner and Argyropoulos 1975), wound healing issues (e.g., torpid wounds, decubitus) (Buchmayer et al 2011;Mochida et al 1989;Neinhardt 1967;Schonwald et al 1991) and mucosal lesions after radiation (Basu et al 1985;Bauer and Locker 1974;Beetz et al 1996;Buchmayer et al 2011;Spessotto et al 1993).…”

Section: Introductionmentioning

confidence: 99%

Actovegin® reduces PMA-induced inflammation on human cells

et al. 2020

View full text Add to dashboard Cite

Purpose The effect of Actovegin® was investigated on PMA- and LPS-induced human peripheral blood mononuclear cells (PBMCs). Methods PBMCs (1 × 106 cells/ml) from five blood donors (2 f, 3 m; 45–55 years) were grown in medium and exposed to Actovegin® in the presence or absence of PMA or LPS. Supernatants were collected to assess the concentration of cytokines (TNF-α, IL-1beta, IL-6 and IL-10). The reactive oxygen species (ROS) were assessed by a ROS-GloTM H2O2 assay. Results Stimulation of cells by PMA or LPS (without Actovegin®) significantly increased the secretion of IL-1beta, IL-6, IL-10 and TNF-α from PBMCs, compared to controls. Pre-treatment of cells with Actovegin® (1, 5, 25, 125 µg/ml) plus PMA significantly decreased the secretion of IL-1beta from PBMCs, compared to controls (PMA without Actovegin®). In contrast, addition of Actovegin® (1, 5, 25, 125 and 250 µg/ml) plus LPS did not alter the IL-1beta production, compared to controls (LPS without Actovegin®). TNF-α, IL-6 and IL-10 do not contribute to the reduction of inflammatory reactions with Actovegin®. Conclusions Actovegin® can reduce the PMA-induced IL-1beta release and the ROS production from PBMCs. These findings may help to explain the clinically known positive effects of Actovegin® on athletic injuries with inflammatory responses (e.g., muscle injuries, tendinopathies).

show abstract

The radioprotective effect of solcoseryl

Cited by 4 publications

References 1 publication

Actovegin®: a biological drug for more than 5 decades

Actovegin®: a biological drug for more than 5 decades

Comprehensive Analytics of Actovegin® and Its Effect on Muscle Cells

Actovegin® reduces PMA-induced inflammation on human cells

Contact Info

Product

Resources

About